Advertisement

AIkido Pharma Inc. AIKI

Set alert

Price alert · AIKI

All alert types
3.56 +3.56 —

Day range unavailable

52-week range unavailable

Open
—
Prev close
0.00
Mkt cap
19.53M
Vol
0
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
-2.37
Beta
0.94
Short ratio
2.31
Inst. own
10.87%
Dividend
0.00
Ex-div date
May 11, 1980
Earnings
Nov 10, 2022
50-d avg
4.35
200-d avg
4.30
1y target
16.00

2Y chart

Chart tools
Interval

Events in this range
  • Nov 10, 2021Earnings: —; estimate -0.51; surprise —%
  • Mar 28, 2022Earnings: —; estimate 0; surprise —%
  • May 16, 2022Earnings: —; estimate -0.34; surprise —%
  • Jun 7, 2022Split: 1 for 17
  • Aug 12, 2022Earnings: —; estimate -0.68; surprise —%
  • Nov 10, 2022Earnings: —; estimate -0.77; surprise —%
  • Nov 11, 2022Rating: HC Wainwright & Co. · — → Buy
Signals (51)
NameDateAgo
MACD: Buy SignalDec 6, 20223 years ago
RSI: OversoldNov 4, 20223 years ago
SMA: BearishOct 19, 20224 years ago
SMA: BullishOct 13, 20224 years ago
SMA: BearishOct 11, 20224 years ago
SMA: BearishOct 11, 20224 years ago
MACD: Sell SignalOct 7, 20224 years ago
SMA: BullishOct 3, 20224 years ago
SMA: BearishSep 30, 20224 years ago
SMA: BullishSep 29, 20224 years ago
SMA: BullishSep 15, 20224 years ago
SMA: BearishSep 13, 20224 years ago
SMA: BullishSep 12, 20224 years ago
MACD: Buy SignalSep 12, 20224 years ago
SMA: BearishAug 30, 20224 years ago
SMA: BullishAug 29, 20224 years ago
SMA: BearishAug 26, 20224 years ago
MACD: Sell SignalAug 26, 20224 years ago
MACD: Buy SignalAug 9, 20224 years ago
SMA: BearishJul 26, 20224 years ago
MACD: Sell SignalJul 20, 20224 years ago
MACD: Buy SignalJun 7, 20224 years ago
MACD: Sell SignalJun 6, 20224 years ago
MACD: Buy SignalMay 31, 20224 years ago
MACD: Sell SignalMay 18, 20224 years ago
MACD: Buy SignalMay 17, 20224 years ago
MACD: Sell SignalMay 12, 20224 years ago
SMA: BearishMay 5, 20224 years ago
SMA: BullishMay 4, 20224 years ago
MACD: Buy SignalMay 2, 20224 years ago
RSI: OversoldApr 25, 20224 years ago
RSI: OversoldApr 18, 20224 years ago
MACD: Sell SignalApr 7, 20224 years ago
SMA: BearishApr 6, 20224 years ago
SMA: BullishMar 28, 20224 years ago
SMA: BearishMar 25, 20224 years ago
SMA: BullishMar 24, 20224 years ago
MACD: Buy SignalFeb 28, 20224 years ago
RSI: OversoldFeb 25, 20224 years ago
MACD: Sell SignalFeb 22, 20224 years ago
RSI: OversoldFeb 18, 20224 years ago
MACD: Buy SignalJan 28, 20224 years ago
RSI: OversoldJan 27, 20224 years ago
MACD: Sell SignalJan 13, 20224 years ago
RSI: OversoldJan 13, 20224 years ago
RSI: OversoldJan 10, 20224 years ago
MACD: Buy SignalJan 3, 20224 years ago
MACD: Sell SignalDec 29, 20214 years ago
RSI: OversoldDec 27, 20214 years ago
RSI: OversoldDec 22, 20214 years ago
RSI: OversoldDec 13, 20214 years ago

Key statistics

Market cap
19.53M
Enterprise value
-27.71M
Trailing P/E
0.00
Forward P/E
-2.37
PEG ratio
0.00
Price / sales
0.00
Price / book
0.22
EPS (TTM)
-1.85
Beta
0.94
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-16.31M
Total cash
46.75M
Total debt
743.00K
Return on equity
-18.01%
Shares outstanding
5.49M
Short % of float
1.39%
50-day average
4.35
200-day average
4.30

Analyst view

Consensus: buy

Buy
Price target (mean) 16.00

Next earnings

Nov 10, 2022

Expected Nov 10, 2022. Consensus EPS estimate -1.11.

Earnings history

Earnings

AIKI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 10, 2022Sep 1, 2022-0.77———
Aug 12, 2022Jun 1, 2022-0.68———
May 16, 2022Mar 1, 2022-0.34———
Mar 28, 2022Dec 1, 20210.00———
Nov 10, 2021Sep 1, 2021-0.51———
Aug 11, 2021Jun 1, 20210.00———

Upgrades / downgrades

AIKI analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2022HC Wainwright & Co.main—Buy
Oct 11, 2021HC Wainwright & Co.init—Buy

About AIkido Pharma Inc.

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on AIKI — it syncs with the Stock Master app.

Insider holders

AIKI insider holders
InsiderRelationLatest transactionDateShares held
BLATTNER GREGORY JAMESDirectorStock Award(Grant)Aug 25, 202212,411
DUDLEY ROBERT FREDERICKDirectorStock Award(Grant)Aug 25, 202212,411
HAYES ANTHONYChief Executive OfficerPurchaseDec 13, 2022176,681
LEDWICK TIM SDirectorStock Award(Grant)Aug 25, 202212,826
LEMIRE PAULDirectorStock Award(Grant)Aug 25, 202212,411
VANDER ZANDEN ROBERT JDirectorStock Award(Grant)Aug 25, 202212,702

Institution ownership

AIKI institution ownership
Holder% heldSharesValueReported
Vanguard Group, Inc. (The)3.53%193,543689.01KSep 29, 2022
Two Sigma Advisers, LP1.58%86,700308.65KSep 29, 2022
Blackrock Inc.1.37%75,275267.98KSep 29, 2022
Dimensional Fund Advisors LP1.05%57,849205.94KSep 29, 2022
Two Sigma Investments, LP0.98%53,595190.80KSep 29, 2022
Geode Capital Management, LLC0.79%43,409154.54KSep 29, 2022

Fund ownership

AIKI fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.02%111,013395.21KSep 29, 2022
Vanguard Extended Market Index Fund1.41%77,589276.22KSep 29, 2022
Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF0.46%25,45790.63KJul 30, 2022
Fidelity Extended Market Index Fund0.43%23,57883.94KOct 30, 2022
DFA U.S. Small Cap Series0.16%8,87231.58KJul 30, 2022
Fidelity Total Market Index Fund0.14%7,41826.41KOct 30, 2022
Advertisement